Starting Wegovy at 0.25 mg — and Why the Climb to 2.4 Is So Slow

The first Wegovy shot is 0.25 mg. You read that number off the side of the pen and think: huh, that's it? By then most people have braced for the version of semaglutide they've seen described online — the one where the weight comes off over a year — and here is a dose so small it feels almost symbolic. A quarter of a milligram, once a week.

Here's the sentence that rarely lands early enough: 0.25 mg isn't "the dose." It's the first rung. The maintenance dose for weight management sits much higher — 2.4 mg once weekly — and the gap between the two is a staircase you climb over months. Once the plan reads as slow by design, most of that early panic quietly drains away. So here's the same staircase, one rung at a time, laid out the way it deserves to be before the first injection rather than after.

So what's that tiny 0.25 mg even for?

On the US FDA label, Wegovy starts at 0.25 mg once weekly for the first four weeks. Then it steps up on a set schedule, roughly every four weeks, until it reaches the maintenance dose. Written out, the climb looks like this:

The first thing that jumps out: 0.25 mg isn't really a "working" dose in the usual sense. It's a warm-up. Weeks one through four exist to let your body meet the drug gently, before the number on the pen starts climbing. Circle week one on a calendar, and the maintenance dose is four steps and roughly four months away.

That reframing does real work. The scale doesn't move much at 0.25 mg for a lot of people, and it's easy to read that as failure. It isn't failure. It's the staircase working exactly as written.

Why the climb is deliberately slow

Here's the part that turns genuinely reassuring once you see it in the label's own words. The slow climb isn't caution for its own sake, and it isn't the drug being timid. The label ties the gradual escalation to one specific goal: reducing the risk of gastrointestinal adverse reactions. In plainer terms — the nausea, the queasiness, the unsettled gut. Going up slowly gives your stomach time to catch up with each new dose.

That's the whole logic. Semaglutide slows how fast your stomach empties, which is part of how it quiets appetite, and it's also why the side effects live mostly in your digestive system. Jump the dose too fast and you get more of that, harder. Step it up gently and your body adapts along the way. The four-week spacing between rungs isn't arbitrary — it's about how long it takes to settle in before the next bump.

So when the plan feels frustratingly slow, it helps to remember what the slowness is buying you: a gut that's far less likely to rebel.

Every step up, the nausea knocks again

The pattern rarely gets spelled out in advance, so here it is. The most common side effects on semaglutide — the ones showing up at an incidence of 5% or more in the trials — are nausea, diarrhea, vomiting, and constipation. Gut stuff, all of it. And they tend to cluster right around a dose increase.

The common version goes like this. The first four weeks at 0.25 mg are fine, almost suspiciously fine. Then the dose moves up to 0.5 mg and the queasiness comes back like an old acquaintance nobody missed. A few rough days, then it fades. You get comfortable. Then 1 mg, and — there it is again. Same shape: a rough stretch after the bump, then a settling.

Here's the mental model that helps. Each rung is a small reset. Your body adapts to one dose, then you hand it a bigger one, so it re-adjusts. And the good news buried in that is the same news that makes the trial data readable. In STEP 1 — the 68-week trial of semaglutide at 2.4 mg — nausea and diarrhea were the most common side effects, and they were typically transient and mild-to-moderate, and they subsided with time.

One honest caveat, because it matters. Those trial percentages are whole-study figures, not a per-step probability. The label doesn't say some fixed share of people vomit at every increase, and there's no honest number to put in its place. What the data supports is softer and truer: the gut symptoms are most common around the climb, and for most people they're temporary. "Most" is not "everyone," which is exactly why the next section exists.

The first time the nausea comes back at 0.5 mg, it's easy to be certain something has gone wrong. By the third rung, it reads as familiar instead — rough for a few days, then quiet. Knowing the shape of it takes most of the fear out.

Going slow is allowed — the label says so

This is the single fact most worth having at the start, so here it is plainly. If a dose isn't sitting well, you don't have to grit your teeth and push up to the next rung on schedule. The US label spells it out: if a patient doesn't tolerate a dose during escalation, consider delaying the next step up by 4 weeks.

Read that twice, because it reframes the whole thing. Slowing down isn't going off-script. Slowing down is in the script. Staying an extra four weeks at 0.5 mg, or at 1 mg, because your body isn't ready yet — that's a documented, label-sanctioned move, not a personal failure and not a sign the drug is wrong for you.

That move gets used often in practice. A dose bump lands harder than usual, and instead of white-knuckling toward the next one, prescriber and patient simply wait. The rung gets held for a few extra weeks. The queasiness settles, and then the next step up is manageable. The staircase has landings. You're allowed to stand on one and breathe.

The flip side of "you're allowed to slow down" is "you don't have to suffer in silence." Transient and mild-to-moderate is the common case, not a promise. If a symptom is severe, or it drags on, or you can't keep fluids down, that's not a rung to tough out — that's a call to your prescriber to adjust the pace or the plan.

What actually helps through a dose bump

None of this is medical advice, and none of it is a trick for powering through symptoms you shouldn't be powering through. It's just the plain, human stuff that makes the rough few days after each increase easier to sit with.

• Smaller meals, more often. A big plate when your stomach is already emptying slowly is asking for trouble. Less food at a time goes down far more easily.
• Easy on the greasy and the heavy. Rich, fatty meals are reliably the ones that turn a manageable day queasy. Nothing has to be cut out dramatically — it's mostly a matter of not scheduling a heavy meal for the day after a dose bump.
• Water, unglamorously. Vomiting and diarrhea pull fluid out of you; constipation wants more in. Either way, sipping through the day helps.
• Treat the days right after a bump as the tender window. The queasiness clusters right after each increase, so that's the stretch to be gentlest about: lighter plans, lighter food.

If your gut symptoms need more than this, that's common too, and there's a fuller playbook worth reading on what helps most with GLP-1 nausea and stomach trouble. And if you're still finding your footing with the whole routine, the first-month timeline on a GLP-1 maps out what those early weeks tend to look like.

Does everyone have to reach 2.4 mg?

No — which catches a lot of people off guard, because from the way it gets talked about, 2.4 mg sounds like a finish line you're obligated to cross.

Here's the nuance. 2.4 mg is the usual maintenance dose for weight management, and it's the top of the ladder most people are climbing toward. But that schedule is a recommendation, and it's individualized. Not everyone ends up at the top. If a lower dose gives you a good balance of effect and tolerability, staying there can be a perfectly reasonable place to land — a conversation for you and your prescriber, not a number you owe anyone.

The goal was never "reach the maximum as fast as possible." The goal is the dose your body accepts. For some people that's 2.4 mg. For others it's a rung below. The staircase has a top, but the top isn't mandatory, and "this is where it felt right to stop" is a real outcome, not a shortfall.

One more guardrail, since it trips people up. This whole 0.25-to-2.4 ladder is the schedule for semaglutide, the molecule in Wegovy. Tirzepatide — the drug in Zepbound and Mounjaro — climbs on a completely different schedule, with its own starting dose and its own rungs. If you're on that one, the tirzepatide titration schedule is its own map. Don't borrow the Wegovy rungs for it.

The safety facts that sit outside the nausea

Gut symptoms get all the airtime because they're what most people feel. But two safety facts have nothing to do with day-to-day queasiness, and they belong in a different mental box entirely. These are US FDA label terms; approvals and exact wording differ from country to country, so your local regulator may frame them differently.

First, the hard stop. Semaglutide carries an absolute contraindication — the FDA's boxed-warning level, the agency's most serious safety flag — for anyone with a personal or family history of medullary thyroid cancer, or the syndrome called Multiple Endocrine Neoplasia type 2 (MEN 2). This isn't a "go slow" situation. It's a "this drug isn't for you" situation, and it's worth surfacing before a first prescription, not after.

Second, one grade down: a warning, not a contraindication. Acute pancreatitis is a known risk, and the label's instruction is direct — if pancreatitis is suspected, stop the drug and get it evaluated. Smaller category than the outright contraindication, but the kind of thing you want to recognize rather than explain away.

And then, in a third box of their own, the everyday gut symptoms we've been talking about. Common, usually temporary, and the thing the slow climb is designed to soften. Three different tiers, and it helps to keep them separate:

The nausea is the part you feel, and the part you'll obsess over. The contraindication is the part you'll never feel and absolutely need to know. Don't let the loud one crowd out the quiet one.

If you're holding your first 0.25 mg pen

If you're standing at the bottom of the staircase — a 0.25 mg pen in hand, wondering why it feels like nothing is happening — here's the short version worth carrying up with you.

That small first dose is the start of a months-long climb, not the whole treatment. The climb is slow on purpose, to spare your gut. The nausea will probably knock again at each step up, and for most people it fades again each time. If a rung is too much, you're allowed to stay on it longer — that's written into the label, not a workaround. You may top out at 2.4 mg, or you may find your place a rung below, and both are fine. And the two things that live outside the nausea — the thyroid-cancer contraindication and the pancreatitis warning — are worth knowing cold.

The staircase isn't a race. The dose your body accepts, at the pace it accepts it, is the whole point. If you want the mechanics of the shot itself down — the where and the how — the self-injection walkthrough covers that ground.

This is information pulled from published clinical trials and the drug's prescribing information, not medical advice — how you climb, when you pause, and where you stop are all conversations for you and the prescriber who knows your history.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app